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To determine the role of Chlamydia trachomatis 
in miscarriage, we prospectively collected serum, 
cervicovaginal swab specimens, and placental samples 
from 386 women with and without miscarriage. Prevalence of 
immunoglobulin G against C. trachomatis was higher in the 
miscarriage group than in the control group (15.2% vs. 7.3%; 
p = 0.018). Association between C. trachomatis–positive 
serologic results and miscarriage remained signifi cant after 
adjustment for age, origin, education, and number of sex 
partners (odds ratio 2.3, 95% confi dence interval 1.1–4.9). 
C. trachomatis DNA was more frequently amplifi ed from 
products of conception or placenta from women who had 
a miscarriage (4%) than from controls (0.7%; p = 0.026). 
Immunohistochemical analysis confi rmed C. trachomatis 
in placenta from 5 of 7 patients with positive PCR results, 
whereas results of immunohistochemical analysis were 
negative in placenta samples from all 8 negative controls 
tested. Associations between miscarriage and serologic/
molecular evidence of C. trachomatis infection support its 
role in miscarriage.
The incidence of Chlamydia trachomatis infection has dramatically increased during the past 10 years (1). 
Mostly asymptomatic, untreated C. trachomatis infections 
are responsible for a large proportion of salpingitis, pelvic 
infl ammatory disease, ectopic pregnancy, and infertility in 
women. C. trachomatis is a recognized agent of preterm 
labor and premature rupture of membranes (2,3). However, 
its role in miscarriage is unclear (2,3).
C. trachomatis has been isolated or detected in 
cervical smear, urine (4–6), or products of conception 
(7,8). Nevertheless, none of these studies demonstrated 
association between isolation of C. trachomatis and 
miscarriage. However, culturing C. trachomatis is 
technically diffi cult, given its strict intracellular life cycle. 
Even with molecular approaches, detecting C. trachomatis 
can be diffi cult because of PCR inhibitors or low number 
of copies often present in the lesions (4–7). Moreover, 
infection could be localized at deeper sites not amenable 
to sampling (9).
Several studies have reported a higher prevalence 
of C. trachomatis antibodies in spontaneous (10,11) or 
recurrent (2,9,11,12) miscarriages. The inability to detect 
immunoglobulin (Ig) M or to isolate C. trachomatis from 
any of these seropositive patients might suggest that 
Chlamydia spp. are not directly associated with miscarriage 
(9,12). Other seroepidemiologic studies have failed to fi nd 
any correlation between C. trachomatis and spontaneous 
(13–16) or recurrent miscarriage (17,18).
The main purpose of this study was to investigate 
whether C. trachomatis is associated with miscarriage. 
We used molecular, serologic, and immunohistochemical 
approaches to compare evidence of present and past 
C. trachomatis infection in women with or without 
miscarriage.
Materials and Methods
During November 2006–June 2009, a total of 386 
women were prospectively enrolled at the obstetric 
department of the University Hospital of Lausanne 
(Lausanne, Switzerland). The miscarriage group comprised 
125 women consulting at the emergency gynecology ward 
for an acute miscarriage. The control group comprised 
261 women attending the labor ward with an uneventful 
pregnancy and without any history of miscarriage, stillbirth, 
or preterm labor. All women gave written consent, and the 
local ethical committee approved the study.
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C. trachomatis and Miscarriage
We collected demographic and obstetric data 
prospectively. Placenta (or products of conception in cases 
of miscarriage), cervicovaginal swab specimens, and serum 
were sampled at the time of labor and of miscarriage.
All serum samples were tested for IgG and IgA against 
C. trachomatis with the Ridascreen Chlamydia IgG/
IgA Kit (R-biopharm, Darmstadt, Germany) according 
to the manufacturer’s instructions and by using Dynex 
DSX (Magellan Biosciences, Chantilly, VA, USA). 
Cervicovaginal swabs and placenta were extracted by using 
QIAamp DNA Mini kit (QIAGEN, Hilden, Germany). 
Samples were screened for C. trachomatis DNA by using a 
TaqMan real-time PCR specifi c for the cryptic plasmid of 
C. trachomatis, as described (19). A PCR inhibition control 
was used to verify that absence of amplifi cation was not 
caused by PCR inhibitors. Only 1 of the 386 PCR inhibition 
controls was negative. This sample was thus retested at a 
1:10 dilution.
Hematoxylin and eosin–stained histologic sections of 
all placentas were investigated for deciduitis, vasculitis, 
endometritis, or chorioamnionitis. Histologic samples 
were read blindly by a pedopathologist (M.-C.O.). Samples 
positive for C. trachomatis by real-time PCR were tested 
by immunohistochemical analysis (IHC). Presence of C. 
trachomatis on histologic sections was assessed by using 
a specifi c mouse monoclonal antibody, as described (20). 
To test the placental specimens, we used a commercial 
Chlamydiaceae family–specifi c monoclonal antibody 
directed against the chlamydial lipopolysaccharide (clone 
AC1-P; Progen, Heidelberg, Germany) at a dilution of 
1:200. Detection was performed with the Dako ChemMate 
detection Kit (Dako, Glostrup, Denmark) according to 
the manufacturer’s instructions. Antigen retrieval was 
performed by 10-min enzyme digestion (proteinase K; 
Dako). Immersion of the slides in peroxidase-blocking 
solution for 5 min at room temperature resulted in 
blocking of endogenous peroxidase activity. Specimens 
were incubated with primary antibody for 1 h. Sections 
were incubated for 10 min at room temperature with the 
link-antibody (Dako), followed by 10 min incubation 
with horseradish peroxidase (Dako) and fi nally developed 
in 3-amino, 9-ethyl-carbazole substrate solution for 
10 min at room temperature and counterstained with 
hematoxylin. Using the antibody diluent instead of the 
primary antibody, we performed a negative control of 
each section. Moreover, 8 placentas from C. trachomatis 
PCR-negative patients were randomly selected as negative 
controls. IHC was blindly read by 2 pathologists with 
experience in chlamydial IHC (S.B., N.B.) and confi rmed 
by a pedopathologist (M.-C.O.).
We compared demographic data and risk factors of 
patients with and without miscarriage or C. trachomatis 
infection by the Pearson χ2 test (or the Fisher exact test 
when indicated) for categorical variables. For continuous 
variables, medians were compared by the Wilcoxon-
Mann-Whitney test. Multivariate logistic regression was 
performed to identify factors independently associated with 
miscarriage or with C. trachomatis infection. Statistical 
analyses were performed by using Stata version 10.0 
(StataCorp LP, College Station, TX, USA).
Results
Of 395 patients, 9 (2.3%) were excluded because of 
missing serum or vaginal swab samples. Sociodemographic 
data for the remaining 386 women are shown in Table 1.
A total of 16 (4.2%) patients were positive for IgG and 
IgA against C. trachomatis, 22 (5.7%) were positive only 
for IgG against C. trachomatis, and 4 (1.0%) were positive 
only for IgA against C. trachomatis. Prevalence of IgG 
against C. trachomatis was higher in the miscarriage group 
(15.2%) than in the control group (7.3%; p = 0.018) (Table 
1). This association between miscarriage and IgG against 
C. trachomatis remained signifi cant, even after adjustment 
for age, origin, education, and number of sex partner (odds 
ratio [OR] 2.3, 95% confi dence interval [CI] 1.1–5.1). 
Similarly, prevalence of IgA against C. trachomatis was 
higher in the miscarriage group (8.0%) than in the control 
group (3.8%), but this trend was not signifi cant (p = 0.091) 
by univariate analysis. When adjusted for age, origin, 
education, and number of sex partners, the association 
between miscarriage and IgA against C. trachomatis was 
signifi cant (OR 2.7, 95% CI 1.1–7.4).
Multivariate logistic regression including all 
sociodemographic variables (Table 1) and C. trachomatis 
IgG serologic results identifi ed 5 independent factors 
positively or negatively associated with miscarriage: C. 
trachomatis IgG–positive serologic results (OR 2.3, 95% 
CI 1.1–4.9), age >35 years (OR 2.7, 95% CI 1.6–4.4), 
European origin (OR 0.3, 95% CI 0.2–0.5), marriage (OR 
0.4, 95% CI 0.2–0.7), and 1 lifetime sex partner (OR 0.4, 
95% CI 0.2–0.7).
C. trachomatis DNA was more frequently amplifi ed 
from products of conception or placenta from women 
with miscarriage (5 [4.0%] women) than from controls 
(2 [0.7%], p = 0.026). Most patients with a positive PCR 
result for placenta also had a positive result for vaginal 
swab specimens (Table 2). Six of the 7 patients with C. 
trachomatis DNA in the cervicovaginal swab specimen 
also had positive fi ndings in the placenta. Thus, again, 
cervicovaginal C. trachomatis DNA was more often 
detected in patients from the miscarriage group (n = 5, 4.0%) 
than from the control group (n = 2, 0.7%; p = 0.026). All 
7 patients with C. trachomatis DNA in the cervicovaginal 
swab also exhibited IgG against C. trachomatis, whereas 
all patients but 1 with C. trachomatis DNA in the placenta 
exhibited IgG against C. trachomatis (Table 2). Both 
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patients with C. trachomatis DNA and IgG and IgA against 
C. trachomatis belonged to the miscarriage group.
All placentas were analyzed for infl ammation (Figure 
1). In the basal plate, infl ammatory cells (deciduitis) were 
present in 15 (39.5%) of 38 patients and 91 (26.1%) of 
348 patients with and without C. trachomatis IgG–positive 
serologic results, respectively (p = 0.081). This trend 
was observed to a lesser extent when C. trachomatis IgA 
serologic results were considered (7 [35.0%] of 20 vs. 99 
[26.3%] of 376; p = 0.446).
All 8 persons with samples positive for C. trachomatis 
by real-time PCR in the placenta (n = 7) or cervicovaginal 
swab specimen (n = 7) were tested by IHC (Table 2; Figure 
2). C. trachomatis was confi rmed in 4 of 6 placentas from 
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Table 1. Characteristics of 386 women, by miscarriage history, in a study of the role of Chlamydia trachomatis in miscarriage, 
University Hospital of Lausanne, Lausanne, Switzerland, November 2006–June 2009* 
Characteristic Control group, no. (%), n = 261 Miscarriage group, no. (%), n = 125 p value
Age, y†
 <35 194 (74.3) 71 (56.8) 0.001
 >35 67 (25.7) 54 (43.2)
No. pregnancies‡
 1 141 (54.0) 38 (30.4) <0.001
 2 78 (29.9) 32 (25.6)
 >2 42 (16.1) 55 (44.0)
Parity§
 0 160 (61.3) 62 (49.6) 0.066
 1 72 (27.6) 41 (32.8)
 >1 29 (11.1) 22 (17.6)
Origin
 European 217 (83.1) 69 (55.2) <0.001 
 Non-European 44 (16.9) 56 (44.8)
Marital status
 Married 201 (77.0) 90 (72.0) 0.193 
 Single 49 (18.8) 24 (19.2)
 Divorced 11 (4.2) 11 (8.8)
Education
 Non–university studies 170 (65.1) 96 (76.8) 0.025 
 University studies 91 (34.9) 29 (23.2)
No. lifetime sex partners
 1 58 (22.2) 37 (29.6) 0.031 
 2 or 3 43 (16.5) 24 (19.2)
 4–6 45 (17.2) 10 (8.0)
 >6 36 (13.8) 10 (8.0)
 No answer 79 (30.3) 44 (35.2)
Previously used contraceptive method
 Pill 101 (38.7) 36 (28.8) 0.093 
 Condoms 68 (26.1) 34 (27.2)
 Other 19 7.3) 6 (4.8)
 Never used contraception 73 (28.0) 49 (39.2)
Smoking status
 Nonsmoker 224 (85.8) 106 (84.8) 0.877 
 Smoker 37 (14.2) 19 (15.2)
C. trachomatis serologic results
 IgG+ 19 (7.3) 19 (15.2) 0.018
 IgA+ 10 (3.8) 10 (8.0) 0.091
 IgG+ and IgA+ 7 (2.7) 9 (7.2) 0.037
 IgG+ or IgA+ 22 (8.4) 20 (16.0) 0.025
C. trachomatis PCR 
 Cervicovaginal swab 2 (0.8) 5 (4.0) 0.026
 Placenta 2 (0.8) 5 (4.0) 0.026
>1 PCR positive 2 (0.8) 6 (4.8) 0.009
*Ig, immunoglobulin. 
†Age, y, mean + SD: controls, 31.5 + 5.0; women with miscarriage, 33.3 + 6.1; p = 0.002. 
‡No. pregnancies, mean + SD: controls, 1.7 + 0.9; women with miscarriage, 2.6 + 0.5; p<0.001. 
§Parity, mean + SD: controls, 0.5 + 0.8; women with miscarriage, 0.8 + 1.0; p = 0.008. 
C. trachomatis and Miscarriage
women with miscarriage and in 1 of 2 placentas from 
women with uneventful pregnancies, whereas none of 
the 8 C. trachomatis DNA–negative controls randomly 
selected exhibited the bacteria by IHC. C. trachomatis 
predominantly localized around endometrial glands of 
the chorion (Figure 2), associated with different degree of 
infl ammation (Figure 1).
We also compared characteristics of patients with (n 
= 38) and without (n = 348) C. trachomatis IgG–positive 
serologic results. Number of pregnancies, parity, marital 
status, education, number of lifeltime sex partners, and 
smoking status were all associated with C. trachomatis IgG–
positive serologic results by univariate analysis. Women 
who declined to provide information on the number of sex 
partners had a C. trachomatis IgG prevalence of 12.2%, 
whereas none of the 95 women who reported having 1 sex 
partner had C. trachomatis IgG–positive serologic result. 
In multivariate analyses, independent factors positively or 
negatively associated with C. trachomatis IgG–positive 
serologic results were >2 lifetime sex partners (OR 3.3, 95% 
CI 1.4–7.7), divorced women (OR 4.9, 95% CI 1.7–14.3), 
European origin (OR 0.4, 95% CI 0.2–0.9), and attending 
a university (OR 0.2, 95% CI 0.1–0.6). Age and smoking 
were not independently associated with C. trachomatis 
IgG–positive serologic results.
Discussion
We found an association of spontaneous miscarriage 
with serologic (p = 0.018) and molecular (p = 0.026) 
evidence of C. trachomatis infection. Moreover, C. 
trachomatis in the placenta was documented by specifi c 
IHC. C. trachomatis was mainly localized in the epithelial 
cells of endometrial glands.
Several studies have failed to document an association 
between C. trachomatis and spontaneous (13–16) or 
recurrent miscarriage (17,18). However, these studies were 
conducted >10 years ago, i.e., before the recent dramatic 
increase in the prevalence and incidence of C. trachomatis 
infection (1,21,22). Because of improved statistical power, 
such increased prevalence might indicate an association 
between C. trachomatis infection and adverse pregnancy 
outcomes. Second, sensibility and specifi city of diagnostic 
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Table 2. Clinical history and serologic, PCR, and IHC results of 8 women with samples positive for Chlamydia trachomatis by real-time 














 235 2 0 8 + – + + + Lymphocytes in chorion, acute 
endometritis
 355 1 0 7 + – + + – Polymorphonuclear cells  
in decidua
 518 2 0 6 + – + + + Subchorial fibrin, lymphocytes 
in decidua
 564 5 2 12 + + + + + Lymphocytes in decidua
 568 2 1 6 - – + – – Lymphocytes in decidua, 
hemorrhagic necrosis
 460 1 0 11 + + – + + Presence of eosinophils
Control group 
 35 2† 1 37 + – + + – Histiocytes, rare calcifications
 390 1 1 40 + – + + + Chronic deciduitis
*Ig, immunoglobulin; IHC, Immunohistochemical analysis; +, positive; –, negative. 
†One previous termination of pregnancy. 
Figure 1. Placental histologic results from 3 women with real-time PCR–positive results for Chlamydia trachomatis (Table 2). A) Case-
patient 390; B) case-patient 235; C) case-patient 564. Histologic analysis shows different degree of periglandular lymphocytes infi ltration, 
with a microabscess in panel B. Original magnifi cations ×600 except panel B (×400).
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methods have also improved during the past decade. Thus, 
the high C. trachomatis seroprevalence observed in the 
control group of several older studies, ranging from 28% 
to 53% (16,17) was likely to have resulted from a low 
specifi city of the serologic test used at that time. The 
Chlamydia IgG/IgA kit from R-biopharm we used in the 
present study exhibited better specifi city than did 4 other 
commercially available tests for detecting IgG against C. 
trachomatis (23) and is thus more likely to identify a slight 
but true association. Moreover, the sensitivity of the C. 
trachomatis TaqMan real-time PCR we used here is high, 
detecting even <10 DNA copies. This validated assay also 
detects strains that contain a recently identifi ed 350-bp 
deletion in the cryptic plasmid (24,25) because the 71-bp 
DNA fragment amplifi ed is 93 bp downstream from the 
deletion (19).
The serologic association we observed is unlikely to be 
due to cross-reactivity with other chlamydial species such 
as C. abortus (previously classifi ed as C. psittacci senso 
lato) because we also observed a molecular association 
with miscarriage. Moreover, the PCR we used was specifi c 
at species level because the C. abortus genome contains 
no cryptic plasmid. Finally, C. abortus has been only 
infrequently associated with miscarriages in humans (26), 
mostly after zoonotic exposure.
Miscarriage could be induced by a persistent 
asymptomatic C. trachomatis infection spreading to the fetal 
tissue or endometrium. Relatively few miscarriages occur 
during C. trachomatis primary infection, which explains 
the absence of association with IgA. That several patients 
exhibited C. trachomatis–positive serologic results without 
C. trachomatis DNA suggests that miscarriage might also 
occasionally be induced by damage from a past chlamydial 
infection or persistent C. trachomatis antibodies that might 
interfere with embryonic antigens (2).
A limitation of our study was the absence of 
investigation of other infectious etiology of miscarriage. 
Some viruses can produce chronic or recurrent maternal 
infection. In particular, cytomegalovirus during pregnancy 
can reach the placenta by hematogenous spread or by 
ascending route from the cervix. Parvoviruses also have 
been implicated in the development of repeated fetal loss. 
Among bacterial infections, Ureaplasma urealyticum, 
Mycoplasma hominis, and bacterial vaginosis have been 
mostly associated with miscarriages (27). In addition, 
several intracellular bacteria such as Coxiella burnettii 
(28), Brucella abortus (29), and Waddlia chondrophila 
(11) have been associated with miscarriage.
Our study shows an association between miscarriage 
and molecular and serologic evidence of C. trachomatis 
infection. Several previous studies failed to document such 
an association probably because of the limited number of 
patients in some of these studies resulting from the lower 
prevalence of C. trachomatis infection in the late 20th 
century and to lower sensitivity or specifi city of diagnostic 
methods available at that time. The results of our study 
suggest that all women experiencing a miscarriage should 
be screened for C. trachomatis infection and, if positive, 
adequately treated to prevent recurrent miscarriages. 
Moreover, preconceptional screening might be proposed to 
reduce the prevalence of this adverse pregnancy outcome.
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C. trachomatis–infected cells from endometrial glands. Original magnifi cation ×600.
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